A Phase 2 Trial of Fluzoparib Combined With Apatinib Versus Fluzoparib Monotherapy in Treatment With Relapsed Ovarian Cancer Patients

Exclusion Criteria

• •1. Prior treatment with a poly (ADP-ribose) polymerase (PARP) inhibitor or Apatinib.For exploratory cohort ，patients who received PARP inhibitor are eligible;
• •2. Prior malignancy unless curatively treated and disease-free for \> 5 years prior to study entry. Prior adequately treated non-melanoma skin cancer, in situ cancer of the cervix allowed;
• •3. Radiation or anti-hormonal therapy or anticancer therapy within 14 days before first administration;
• •4. Known to be human immunodeficiency virus positive;
• •5. Known active hepatitis C virus, or known active hepatitis B virus;
• •6. Untreated and/or uncontrolled brain metastases;
• •7. Patients with clinical symptoms of cancer ascites, pleural effusion, who need to drainage, or who have undergone ascites drainage within 3 months prior to the first administration;
• •8. Pregnant or breast-feeding women.